91 related articles for article (PubMed ID: 12415634)
1. Lack of toxicity of EGFR antisense gene therapy.
Zeng Q; Kanter PM; Dhir R; Gooding WE; Huang L; Grandis JR
J Exp Ther Oncol; 2002; 2(3):174-86. PubMed ID: 12415634
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter.
He Y; Zeng Q; Drenning SD; Melhem MF; Tweardy DJ; Huang L; Grandis JR
J Natl Cancer Inst; 1998 Jul; 90(14):1080-7. PubMed ID: 9672256
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy.
Thomas SM; Zeng Q; Dyer KF; Suscovich TJ; Kanter PM; Whalen JD; Watkins SF; Grandis JR
Cancer Gene Ther; 2003 Jul; 10(7):518-28. PubMed ID: 12833132
[TBL] [Abstract][Full Text] [Related]
5. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.
Xing X; Liu V; Xia W; Stephens LC; Huang L; Lopez-Berestein G; Hung MC
Gene Ther; 1997 Mar; 4(3):238-43. PubMed ID: 9135737
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
Lai SY; Koppikar P; Thomas SM; Childs EE; Egloff AM; Seethala RR; Branstetter BF; Gooding WE; Muthukrishnan A; Mountz JM; Lui VW; Shin DM; Agarwala SS; Johnson R; Couture LA; Myers EN; Johnson JT; Mills G; Argiris A; Grandis JR
J Clin Oncol; 2009 Mar; 27(8):1235-42. PubMed ID: 19204206
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
Li M; Ye C; Feng C; Riedel F; Liu X; Zeng Q; Grandis JR
Clin Cancer Res; 2002 Nov; 8(11):3570-8. PubMed ID: 12429648
[TBL] [Abstract][Full Text] [Related]
8. Receptor-mediated delivery of an antisense gene to human brain cancer cells.
Zhang Y; Jeong Lee H; Boado RJ; Pardridge WM
J Gene Med; 2002; 4(2):183-94. PubMed ID: 11933219
[TBL] [Abstract][Full Text] [Related]
9. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
10. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
11. An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.
Sugawa N; Ueda S; Nakagawa Y; Nishino H; Nosaka K; Iwashima A; Kurimoto M
J Neurooncol; 1998 Sep; 39(3):237-44. PubMed ID: 9821109
[TBL] [Abstract][Full Text] [Related]
12. Antisense gene therapy of brain cancer with an artificial virus gene delivery system.
Zhang Y; Zhu C; Pardridge WM
Mol Ther; 2002 Jul; 6(1):67-72. PubMed ID: 12095305
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Alper O ; Bergmann-Leitner ES; Bennett TA; Hacker NF; Stromberg K; Stetler-Stevenson WG
J Natl Cancer Inst; 2001 Sep; 93(18):1375-84. PubMed ID: 11562388
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
15. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
16. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA
Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819
[TBL] [Abstract][Full Text] [Related]
17. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K
Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520
[TBL] [Abstract][Full Text] [Related]
18. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
[TBL] [Abstract][Full Text] [Related]
19. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
Wang S; Lee RJ; Cauchon G; Gorenstein DG; Low PS
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3318-22. PubMed ID: 7724560
[TBL] [Abstract][Full Text] [Related]
20. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
